Key Protein Discovery in Childhood Leukemia
Overview of Childhood Leukemia
Medical scientists in the United States have identified a crucial protein linked to childhood leukemia, as detailed in their recent publication in *Genes & Development*. Childhood leukemia is recognized as the most prevalent cancer among children in Canada, characterized by the abnormal proliferation of white blood cells. This condition arises when atypical white blood cells develop in the bone marrow, leading to the formation of leukemia cells. These cells proliferate rapidly within the bloodstream, hindering the production of normal red blood cells, white blood cells, and platelets. Consequently, affected children may experience a heightened risk of infections and various health complications.
Statistics on Childhood Leukemia in Canada
According to the Canadian Cancer Society, approximately 1,500 Canadian children aged between 0 to 14 years were diagnosed with leukemia between 2009 and 2013. Among these cases, around 1,300 children were identified with acute lymphoblastic leukemia and acute myelogenous leukemia, resulting in approximately 115 fatalities. Notably, the current survival rate for childhood leukemia stands at approximately 30%. Identified risk factors include genetic syndromes, exposure to radiation, and high birth weight. Symptoms of acute leukemia often manifest rapidly within days or weeks, presenting as fatigue, frequent infections, swollen lymph nodes, difficulty breathing, and overall weakness.
Innovative Regulation of Key Protein in Leukemia
Research Findings on MLL1 Protein
A recent study from a team of medical scientists at Northwestern University has unveiled a method to regulate the key protein associated with leukemia. By stabilizing the mixed-lineage leukemia gene, MLL1, the researchers were able to slow the progression of leukemia in a mouse model. This preclinical research sheds light on the direct regulation of MLL1’s stability through its cleavage by the enzyme taspase1, which is encoded by the TASP1 gene in humans.
Implications for Clinical Therapy
This groundbreaking discovery presents promising opportunities for advancing treatment options for childhood leukemia. However, further clinical studies are essential to validate the safety and effectiveness of the proposed therapy.
Reference
Zhao, Z. et al. Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia. *Genes & Development*, 2018;33:61-74. DOI: 10.1101/gad.319830.118.